Caplyta vs Vraylar

Caplyta (lumateperone) was reviewed by the FDA for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, both as monotherapy and as adjunctive therapy. Its review highlighted a statistically significant improvement in MADRS Total Score, with an LS mean difference versus placebo of -4.6. Vraylar (cariprazine) was reviewed for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults, and also as adjunctive therapy to antidepressants for major depressive disorder (MDD). For bipolar depression, the review noted a MADRS placebo-subtracted change ranging from -1 to -2.5.

These drugs were studied in separate trials with distinct designs, populations, and timepoints. For example, Caplyta's review cited a MADRS Total Score LS mean difference versus placebo of -4.6, while Vraylar's review noted a MADRS placebo-subtracted change of -1 to -2.5. The trials also differed in their specific comparator arms and the duration of observation for various endpoints. It is crucial to understand that these figures are not from head-to-head comparisons, and therefore, no direct comparison or implication of superiority between the two drugs can be made.